Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Acute Decompensated Heart Failure, Obstructive Sleep Apnea, Motivational Enhancement, PAP Adherence
Interventions
Telemedicine Intensive Motivational Enhancement
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Heart Failure, Acute Decompensated Heart Failure
Interventions
Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Acute Decompensated Heart Failure
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
Interventions
AirSense™ 10 AutoSet, Standard Medical Therapy
Device · Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Conditions
Heart Failure, Heart Failure - NYHA II - IV, Heart Failure Acute, Acute Heart Failure (AHF)
Interventions
Furosemide intravenous solution
Drug
Lead sponsor
Lakeland Regional Health Systems, Inc.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lakeland, Florida
Terminated No phase listed Observational

Assay to Measure Beta Blocker Adherence

NCT05251974
Conditions
Congestive Heart Failure, Medication Adherence
Interventions
Quest beta blocker assay
Diagnostic Test
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Acute Decompensated Heart Failure
Interventions
Ularitide, Placebo
Drug
Lead sponsor
Cardiorentis
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
39
States / cities
Huntsville, Alabama • Montgomery, Alabama • Sacramento, California + 34 more
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Congestive Heart Failure, Decompensated Heart Failure
Interventions
CardioSpire (Respirix) Device
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Acute Heart Failure, Decompensated Heart Failure
Interventions
subcutaneous furosemide and sc2wear device
Combination Product
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 8 more
Conditions
Acute Decompensated Heart Failure, Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Alere San Diego
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Diego, California • Kansas City, Kansas • Detroit, Michigan + 2 more
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo to Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • Torrance, California + 25 more
Completed No phase listed Observational

SURPASS Impella 5.5 Study

NCT05100836
Conditions
Cardiogenic Shock, Acute Decompensated Heart Failure
Interventions
Impella 5.5
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 11 more
Conditions
Renal Insufficiency, Congestive Heart Failure
Interventions
tonapofylline, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
68
States / cities
Huntsville, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 64 more
Completed Not applicable Interventional

Cardionomic STOP-ADHF Study

NCT04814134
Conditions
Acute Decompensated Heart Failure
Interventions
CPNS Therapy, Standard of care
Device · Other
Lead sponsor
Cardionomic Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Indianapolis, Indiana • Akron, Ohio • Cincinnati, Ohio + 6 more
Terminated Not applicable Interventional Results available

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874
Conditions
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Interventions
MV ASV, Optimized Medical Treatment
Device · Drug
Lead sponsor
ResMed
Industry
Eligibility
21 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Huntsville, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Completed Not applicable Interventional Results available

Benefits of µCor in Ambulatory Decompensated Heart Failure

NCT03476187
Conditions
Heart Failure
Interventions
µCor
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
21 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
57
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Long Beach, California + 49 more
Conditions
Acute Heart Failure
Interventions
sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
Completed Phase 2Phase 3 Interventional Results available

Interleukin-1 Blockade in Recently Decompensated Heart Failure

NCT01936909
Conditions
Heart Failure
Interventions
Anakinra (weeks 1-2), Anakinra (weeks 3-12), Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Completed No phase listed Observational Accepts healthy volunteers

Monocyte Phenotypic Changes in Heart Failure

NCT02997462
Conditions
Heart Failure, Decompensated Heart Failure
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed No phase listed Observational

Shear Wave Elastography

NCT04493346
Conditions
Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Acute Decompensated Heart Failure; Renal Dysfunction
Interventions
SLV320, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Alameda, California • Banning, California • Inglewood, California + 24 more
Conditions
Heart Failure
Interventions
Cardiac rehab
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota